Abstract
The most important methodological approaches to immunopharmacology have been described in the preceding chapters of this book. By way of conclusion, this final chapter will be devoted to an evaluation of current immunotherapeutic methods from the clinical viewpoint. On the one hand, such an evaluation must be based on past therapeutic needs which at the present time are not satisfied at all or only to a limited extent. In this context, one is tempted to make some tentative predictions on the further development of immunopharmacology and on the therapeutic options that this discipline will open. In order to restrict the amount of speculation inherent in such predictions, such extrapolations must be confined to a rather narrow time frame. In addition they must be based on known facts. Our predictions will be limited to approximately 10 years, which is the time span needed to find and to develop a new drug. Projects which are at present underway in the laboratories of major pharmaceutical manufacturers, biotechnology companies and some university laboratories will be the starting points for our future projections. Anything which is not recognizable today in at least rough outline will hardly have matured into a therapeutic drug by the end of this century.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adorini L, Muller S, Cardinaux F, Lehmann PV, Falcioni F, Nagy ZA (1988): In vivo competition between self peptides and foreign antigens in T-cell activation. Nature, Vol 334, 623–625.
Bocci V (1985): The physiological interferon response. Immunology Today, Vol 6, No 1, 7–9.
Boss MA, Wood CR (1985): Genetically engineered antibodies. Immunology Today, Vol 6, No 1, 12–13.
Bussel JB (1984): The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease. Brit J Haematol, Vol 56, 1–7.
Cahill J, Hopper KE (1982): Immunoregulation by macrophages: Differential secretion of prosta-glandin E and interleukin-1 during infection with Salmonella enteritidis. Cellular Immunology, Vol 67, 229–240.
Dattwyler RJ (1982): T cell antigens defined by monoclonal antibodies: A review. Plasma Ther Tranfus Technol, Vol 3, 369–374.
Dayer-Metroz M-D, Wollheim CB, Seckinger P, Dayer J-M (1989): A natural interleukin-1 (IL- 1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. Journal of Autoimmunity, Vol 2, 163–171.
Duff G (1985): Many roles for interleukin-1. Nature, Vol 313, 352–353.
Dwyer JM (1984): Thirty years of supplying the missing link. History of gammaglobulin therapy for immunodeficient states. Amer J Med, March 30, Vol 76, 46–52.
Fischer GW, Weisman LB, Hemming VG, London WT, Hunter KW, Bosworth JM, Sever JL, Wilson SR, Curfman BL (1984): Intravenous immunoglobulin in neonatal group B streptococcal disease. Pharmacokinetic and safety studies in monkeys and humans. Amer J Med, March 30, Vol 76, 117–123.
Fontana A, Hengartner H, de Tribolet N, Weber E (1984): Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. The Journal of Immunology, Vol 132, No 4, 1837–1843.
Jesdinsky HJ et al. (1983): Cooperative group of additional immunoglobulin therapy in severe bacterial infections: Multicenter randomized controlled trial on the efficacy of additional immuno-globulin therapy in cases of diffuse fibrino-purulent peritonitis - study design. Klin Wschr, Vol 61, 445–450.
Kasakura Sh (1985): Suppressor cell induction factor: A new mediator released by stimulated human lymphocytes and distinct from previously described lymphokines. Lymphokine Research, Vol 4, No 1, 31–37.
Kingston AE, Kay JE, Ivanyi J (1985): The effects of prostaglandin E and I analogues on lympho-cyte stimulation. Int J Immunopharm, Vol 7, No 1, 57–64.
Lachman LB (1985): Summary of the fourth international lymphokine Workshop. Lymphokine Research, Vol 4, No 1, 51–57.
LehmannH (1980): Immunglobulinprophylaxe derpost-transfusionellen Hepatitis. Therapiewoche, Vol 30, 5997–6002.
Mannel DN, Parrar J J, Mergenhagen SE (1980): Separation of serum-derived tumoricidal factor from a helper factor for plaque-forming cells. The Journal of Immunology, Vol 124, No3, 1106–1110.
Mannel DN, Meltzer MS, Mergenhagen SE (1980): Generation and characterization of a lipopoly- saccharide-induced and serum-derived cytotoxic factor for tumor cells. Infection and Immunity, Vol 28, No 1, 204–211.
Matthews N (1981): Production of an anti-tumour cytotoxin by human monocytes. Immunology, Vol 44, 135–142.
Mclntyre KW, Unowsky J, DeLorenzo W, Benjamin W (1989): Enhancement of antibacterial resistance of neutropenic, bone marrow-suppressed mice by interleukin-la. Infection and Immunity, Vol 57, 48–54.
Mclntyre KW, Unowsky J, DeLorenzo W et al (1989): Stimulation of hematopoiesis and antibacterial resistance by interleukin-1. Biotherapy, Vol 1, 319–325.
Merluzzi VJ, Last-Barney K (1985): Potential use of human interleukin 2 as an adjunct for the therapy of neoplasia, immunodeficiency and infectious disease. Int J Immunopharm, Vol 7, No 1, 31–39.
Metcalf D (1985): Multi-CSF-dependent colony formation by cell murine hemopoietic line: Specifi-city and action of multi-CSF. Blood, Vol 65, No 2, 357–362.
Moore RN, Pitruzzello FJ, Deana DG, Rouse BT (1985): Endogenous regulation of macrophage proliferation and differentiation by prostaglandins and interferon a/b. Lymphokine Research, Vol 4, No 1, 43 - 50.
Nydegger UE, Blaser K, Hässig A (1984): Antiidiotype immunosuppression and its treatment with human immunoglobulin preparations. Vox Sang, Vol 47, 92 — 95.
Ochs HD, Fischer SH. Wedgwood RJ, Wara MJ, Ammann AJ, Saxon A, Budinger MD, Allred RU, Rousell RH (1984): Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Amer J Med, March 30, Vol 76, 78– 82.
Pasanen VJ (1979): In vitro enhancement of natural cytotoxicity by tumour necrosis serum. Scand J Immunol, Vol 10, No 28, 1284.
Playfair JHL, de Souza JB, Taverne J (1982): Endotoxin induced tumour-necrosis serum kills a subpopulation of normal lymphocytes in vitro. Clin Exp Immunol, Vol 47, 753–755.
Pluznik DH, Cunningham RE, Noguchi PD (1984): Colony-stimulating factor (CSF) controls proliferation of CSF-dependent cells by acting during the Gx phase of the cell cycle. Proc Natl Acad Sci USA, Vol 81, 7451–7455.
Ring J, Bode U, Kadach U, Stix E, Burg G (1983): Gammaglobuline und Allergie. Münch med Wschr, Vol 125, No 14, 289–292.
Ruff MR, Gifford GE (1981): Rabbit tumor necrosis factor: Mechanism or action. Infection and Immunity, Vol 31, No 1, 380–385.
Ruff MR, Gifford GE (1980): Purification and physio-chemical characterization or rabbit tumor necrosis factor. The Journal of Immunology, Vol 125, No 4, 1671–1677.
Sakiel S, Schiller B, Buchowicz L, Kotkowska-Tomanek E (1983): Anti-pseudomonas immuno-globulin. III. Preliminary clinical evaluation. Arch Immunologiae et Therapiae Experimentalis, Vol 31, 517–521.
Schmidt RE, Deicher H (1983): Indikationen zur Anwendung intravenöser Immunglobuline. Dtsch med Wschr, Vol 108, Nr 6, 227–231.
Schumacher K, Maerker-Alzer G, Kleinau T, Hügel W, Dalichau H, Dienst C, Mitrenga D (1982): Passive Immunprophylaxe der Posttransfusionshepatitis durch Immunglobulin-Präparationen. Dtsch med Wschr, Vol 107, Nr 39, 1459–1464.
Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB (1985): Cloning and expression in Escherichia coli of the gene for human tumor necrosis factor. Nature, Vol 313, 803–806.
Shirani KZ, Vaughan GM, McManus AT, Amy BW, McManus WF, Pruitt BA, Mason AD (1984): Replacement therapy with modified immunoglobulin G in burn patients: preliminary kinetic studies. Amer J Med, March 30, Vol 76, 175–180.
Skvarc A, Bone G, Ladurner G, Ott E, Lechner H (1982): Die Bedeutung der Immunglobuline in der Therapie der eitrigen Meningitis. Nervenarzt, Vol 53, 701–704.
Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, McDermott M, Sinha AA, Timmerman L, Steinman L, McDevitt HO (1988): A molecular basis for MHC class II-associated autoimmunity. Science, Vol 240, 1003–1009.
Todd JA, Bell JI, McDevitt HO (1988): A molecular basis for genetic susceptibility to insulindependent diabetes mellitus. Trends in Genetics, Vol 4, No 5, 129–134.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Drews, J. (1990). Clinical Assessment and Perspectives. In: Immunopharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75561-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-75561-3_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75563-7
Online ISBN: 978-3-642-75561-3
eBook Packages: Springer Book Archive